on TRANSGENE (EPA:TNG)
Transgene and ProBioGen Expand Strategic Collaboration
Transgene and ProBioGen have decided to expand their strategic collaboration with a new license agreement. The focus is on ProBioGen's AGE1.CR.pIX® cell line platform, aiming to boost Transgene's manufacturing capabilities. This platform enhances vaccine production efficiency, ensuring cost-effectiveness and scalability. The partnership highlights their commitment to advancing vaccine innovations.
Dr. Alessandro Riva of Transgene expressed satisfaction, citing the expansion as a step towards future clinical needs. ProBioGen's Dr. Volker Sandig emphasized the platform's benefits, such as reproducible and scalable processes, crucial for reliable production. This collaboration marks a significant move in the biotech field, focusing on innovative and scalable solutions for vaccine production.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news